In this proposed human trial, the investigators aim to establish whether 4 weeks of daily consumption of beta-glucan matched meals providing either a high dose or a moderate dose of oat avenanthramides and phenolic acids leads to dose-dependent chronic improvements in markers of CVD risk and gut health relative to an energy matched control intervention in healthy adults with above average blood pressure.
* To investigate the chronic effects of daily intake of oat products on flow mediated dilatation of the brachial artery (FMD; primary endpoint), microvascular endothelial function (measured by laser Doppler iontophoresis), pulse wave analysis, gut microbiota diversity, 24h blood pressure, activity of the renin angiotensin system, markers related to cellular production of nitric oxide and reactive oxygen species, inflammatory cytokines, and further potentially emerging biochemical markers of CVD risk. * To establish if phenolic acids and avenanthramides from oat products exert cardiovascular and microbial effects in a dose dependent manner. * To measure urinary and fecal excretion of avenanthramide and phenolic acid metabolites. To explore correlations between bacterial population changes and CVD risk markers.
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Enrollment
30
High avenanthramide and high phenolic acid, matched with energy and insoluable fibre.
Low avenanthramide and moderate phenolic acid, matched with energy and insoluable fibre.
Control are matched with energy and insoluable fibre.
Hugh Sinclair Unit of Human Nutrition
Reading, United Kingdom
RECRUITINGFlow mediated dilatation
Technique to assess the flexibility of teh endothelium in larger peripheral blood vessels, magnitude of increase in percentage from baseline to after 4 weeks treatment.
Time frame: 20 weeks
Laser Doppler Iontophoresis
Magnitude of increase from Baseline to 4weeks treatment
Time frame: 20 weeks
Gut microbiota changes
Gut microbiota diversity and relative abduance change from Baseline to 4weeks treatment
Time frame: 22 weeks
Plasma nitric oxide analysis
Concentration of nitric oxide in nmol from Baseline to 4weeks treatment
Time frame: 22 weeks
NADPH oxidase activity in neutrophil blood cells
NADPH oxidase activity will be calculated as the difference between values obtained in PMA from Baseline to 4weeks treatment
Time frame: 22 weeks
Inflammatory markers
Inflammatory marker levels change from Baseline to 4weeks treatment
Time frame: 22 weeks
Renin activity
Renin activity in ng/(mL\*hour)
Time frame: 22 weeks
Plasma microparticles
Microparticles in counts/uL
Time frame: 22 weeks
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.
Urine and plasma metabolomic footprint using NMR
Time frame: 22 weeks